<DOC>
	<DOCNO>NCT00636909</DOCNO>
	<brief_summary>The purpose study provide allogeneic stem cell transplantation patient traditionally undergone procedure high incidence treatment related side effect . We hope decrease side effect decrease chemotherapy dose prior transplant ( non-myeloablative , small dose chemotherapy give bone marrow completely eliminate ) use donated stem cell treat cancer blood .</brief_summary>
	<brief_title>Nonmyeloablative Allo SCT Treatment Hematologic Disorders</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Hematologic Diseases</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>Inclusion Criteria Patient : AML , ALL , CML Chronic Phase , Accelerated Phase , Blast Crisis , CLL , MDS , RELAPSED NONHODGKIN 'S OR HODGKIN 'S LYMPHOMA , Aplastic Anemia , Multiple Myeloma , MYELOPROLIFERATIVE DISORDER ( P Vera , CMML , ET Age less 65 year Patients must healthy family member HLAidentical recipient 1 antigen mismatch willing receive course GCSF undergo 24 daily leukaphereses Each patient must sign informed consent willing participate research subject advise nature risk study prior enter protocol Inclusion Criteria Donor : Absence hematologic marrow function relate disease interfere collection sufficient number normal progenitor cell Absence medical condition would pose serious health risk undergo peripheral blood stem cell harvest Negative HIV , HTLV1 , Hepatitis B surface antigen Hepatitis C The donor must blood relation . A prospective related donor must least genotypically HLAA , B , DR identical patient , differ 1 HLAlocus . Exclusion Criteria Patient : Active CNS involvement Females pregnant breast feeding ECOG performance status &gt; 1 . Karnofsky performance status &lt; 80 % LVEF &lt; 40 % Active viral , bacterial , fungal infection Patients seropositive HIV ; HTLV 1 Patients provide informed consent Patients know hypersensitivity E. Coli derive product Exclusion Criteria Donor : A positive HIv infection HTLV 1 test evidence active/persistent viral hepatitis infection . Presence medical condition would pose serious health risk undergo peripheral blood stem cell harvest . Donors know hypersensitivity E. Coli derive product .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>AML</keyword>
	<keyword>ALL</keyword>
	<keyword>CML</keyword>
	<keyword>CLL</keyword>
	<keyword>MDS</keyword>
	<keyword>NHL</keyword>
	<keyword>HODGKIN 'S LYMPHOMA</keyword>
	<keyword>APLASTIC ANEMIA</keyword>
	<keyword>MULTIPLE MYELOMA</keyword>
	<keyword>MYELOPROLIFERATIVE DISORDER</keyword>
	<keyword>ALLOGENEIC</keyword>
	<keyword>STEM CELL TRANSPLANT</keyword>
	<keyword>HEMATOLOGIC DISORDERS</keyword>
	<keyword>CYCLOPHOSPHAMIDE</keyword>
	<keyword>FLUDARABINE</keyword>
	<keyword>CYCLOSPORINE</keyword>
	<keyword>METHOTREXATE</keyword>
	<keyword>G-CSF</keyword>
	<keyword>GVHD</keyword>
	<keyword>ENGRAFTMENT</keyword>
	<keyword>CHIMERISM</keyword>
</DOC>